MedBulletinsAura Celeste
General surgery

Monthly general surgery bulletin — September 28, 2026

🎧 Listen to this issueAudio newscast · 5:57 min

Period covered: August 29 to September 28, 2026. Note for the month: a thin month for randomized trials in general surgery; the weightiest item is a Spanish trial of prophylactic mesh in hepatobiliopancreatic surgery, and two multicenter studies in the British Journal of Surgery are of direct interest for the operating room. No verifiable items in trauma, bariatrics or breast, melanoma or sarcoma surgical oncology within the period. Seven items: we prefer to publish fewer rather than pad.

Abdominal wall and hernia

1. Prophylactic retromuscular mesh reduces incisional hernia after open hepatobiliopancreatic surgery

[Clinical trial] [Spain]
Single-center, double-blind randomized clinical trial (Virgen Macarena Hospital, Seville) in 144 patients with two or more risk factors for incisional hernia undergoing elective hepatobiliopancreatic surgery through a right subcostal laparotomy, randomized to conventional closure or closure reinforced with a retromuscular synthetic mesh. Radiological incisional hernia at 12 months: 5.2% with mesh vs 21% without; at 24 months, 8.1% vs 37.5%. No differences in surgical site occurrences, complications or pain; the J incision was associated with more hernias than the Kocher incision. Published in JAMA Surgery on September 9, 2026; registration NCT07433439.
Why it matters: this is the first randomized evidence specific to the subcostal incision in high-risk patients and the effect size is large, but it is a single center, the abstract gives no hazard or risk ratios with confidence intervals, and follow-up is only two years; it strengthens the recommendation for prophylactic mesh in high-risk laparotomies, now also off the midline.
https://jamanetwork.com/journals/jamasurgery/article-abstract/2853952

Hepatobiliary and pancreas

2. An exosomal signature for preoperative detection of occult liver metastasis in pancreatic cancer

[Publication] [United States / China / Japan / South Korea]
JAMA Surgery published on September 2, 2026 a development and external validation study of a machine-learning model based on circulating exosomal microRNA to predict occult early liver metastasis in pancreatic ductal adenocarcinoma before surgery, accompanied by an invited commentary titled "Toward Biologic Resectability in Pancreatic Cancer." It is a retrospective multicenter case-control study (City of Hope and four centers in China, Japan and South Korea; 372 patients, 2011–2024): the 7-microRNA model achieved an area under the curve of 0.899 in training and 0.876 and 0.862 in the two external cohorts.
Why it matters: the clinical problem is real (non-therapeutic laparotomies for liver metastases not seen on imaging), but the design is a retrospective case-control study and the authors call for prospective validation; until then it should be read as translational research, not as a tool ready to decide whom not to operate on.
https://jamanetwork.com/journals/jamasurgery/fullarticle/2853796

Colorectal and digestive oncology

3. EAGLE-2: digital safe-anastomosis training and 30-day leak after right colectomy

[Publication] [International, 60 countries]
International prospective cohort led by the ESCP and the NIHR Global Surgery Unit, published in the British Journal of Surgery on September 11, 2026: 2,875 patients undergoing right colectomy with a single anastomosis in 332 hospitals across 60 countries. When the operating surgeon had completed the free online safe-anastomosis modules (78% of cases), 30-day anastomotic leak or intra-abdominal collection was 9.1% vs 16.4% (difference 7.3 points; adjusted OR 0.56, 95% CI 0.41–0.78); reoperation adjusted OR 0.64 and readmission 0.65. Overall leak or collection 10.8%, mortality 3.4%.
Why it matters: it is observational and surgeons who complete the course probably differ from those who do not (confounding by indication), but the intervention is free, scalable and consistent with the earlier EAGLE trial; in resource-limited hospitals it is one of the few low-cost measures with a signal on anastomotic leak.
https://academic.oup.com/bjs/article/113/9/znag107/8790652

4. iGreenGO: indocyanine green in D2 lymphadenectomy for gastric cancer, little stage migration

[Publication] [Italy]
Prospective multicenter observational study in 15 Italian referral centers (British Journal of Surgery, September 24, 2026): 316 patients with cT2–4a gastric adenocarcinoma undergoing minimally invasive gastrectomy with D2 lymphadenectomy, after endoscopic peritumoral injection of indocyanine green (2 ml at 0.125 mg/ml) within the previous 20 hours. Residual fluorescence prompted additional dissection in 61 patients (19.3%); extra nodes were retrieved in 47 and were metastatic in 10 (21.3% of those dissected); stage migration in only 3 of 316 (0.9%); median of 38 nodes.
Why it matters: in a Western population with a standardized D2, fluorescence adds nodes but almost never changes the stage and has a high false-positive rate; it does not support routine use outside research protocols, unlike earlier Korean results, and there is no randomized comparator.
https://academic.oup.com/bjs/article/113/9/znag116/8833809

5. Appendectomy versus antibiotics: less subsequent colorectal cancer in a matched cohort

[Meeting] [United States]
Scientific Forum abstract at the American College of Surgeons Clinical Congress 2026 (Washington, DC, September 26–29), presented by Morehouse School of Medicine using the TriNetX network (168 health care organizations): after matching, 15,616 patients treated with appendectomy vs 15,295 treated with antibiotics alone for acute appendicitis. Subsequent colorectal cancer diagnosis in 110 (0.7%) vs 254 (1.7%), a 58% relative reduction. No hazard ratios, confidence intervals or follow-up time are reported; the authors declare no conflicts.
Why it matters: it is retrospective, not peer reviewed and carries an obvious bias (appendectomy removes occult appendiceal and cecal tumors, and the antibiotic group includes patients with an undiagnosed tumor that mimicked appendicitis), so it does not demonstrate a protective effect; it does underline the need for follow-up colonoscopy in adults treated without surgery.
https://www.newswise.com/articles/appendectomy-for-appendicitis-associated-with-58-lower-colorectal-cancer-risk-than-antibiotics-alone

6. Localized appendiceal adenocarcinoma: relapse is uncommon and adjuvant chemotherapy shows no benefit

[Publication] [United States]
Retrospective cohort from MD Anderson (439 patients with stage I–III disease, 2000–2024; 202 operated on at the center) with validation in 128 stage II patients from Memorial Sloan Kettering, published in JAMA Surgery on September 9, 2026. Relapse in 19 of 202 (9.4%): 6% in stage II and 19.5% in stage III. Mucinous (HR 5.60) and enteric-type (HR 6.60) histology versus goblet cell, and pT4 (HR 3.30), were associated with relapse; adjuvant chemotherapy was not associated with better relapse-free survival on multivariable analysis (HR 0.98, 95% CI 0.43–2.28) or overall survival (HR 0.71, 95% CI 0.24–2.10).
Why it matters: the tumor is rare and the study retrospective, with possible indication bias in who received adjuvant therapy, but it adds molecular profiling (TP53 in goblet cell, GNAS in non-goblet tumors) and supports individualizing adjuvant therapy by histology and stage rather than extrapolating from colon cancer.
https://jamanetwork.com/journals/jamasurgery/article-abstract/2853953

Trauma, emergency and bariatric surgery

No verifiable items within the period: no new trial or guideline was identified.

General surgical oncology

No verifiable items this month.

Cross-cutting

7. FDA clears the LigaSure Maryland vessel sealer for the Hugo robot

[Regulatory FDA] [United States]
Medtronic announced on September 16, 2026 the 510(k) clearance of the LigaSure RAS Maryland instrument for the Hugo RAS system, its first robotic vessel sealer in the United States (CE marked since July 2025). Hugo is cleared in the United States only for urology (December 2025); the submissions for general surgery, including hernia repair, and gynecology, whose filing was announced on June 3, remain pending. The company expects to exceed 50,000 Hugo procedures this fiscal year.
Why it matters: it is a necessary step for Hugo to compete in general surgery, but there are no comparative clinical data against Intuitive and the U.S. general surgery indication does not yet exist; for Latin America, what will matter is the cost per procedure and instrument availability, not the press release.
https://www.medtechdive.com/news/fda-clears-vessel-sealing-device-for-medtronics-hugo-robot/830625/
https://news.medtronic.com/2026-09-16-Medtronic-announces-FDA-clearance-for-LigaSure-TM-RAS-Maryland-instrument-on-the-Hugo-TM-RAS-system

Upcoming meetings and dates

American College of Surgeons Clinical Congress 2026: Washington, DC, September 26–29 (ongoing at press time; Scientific Forum abstracts, such as item 5, are not yet peer reviewed). No other dates within the next six weeks could be verified.

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.